• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

呼吸道合胞病毒F序列变异性的功能影响:使用当代呼吸道合胞病毒分离株的比较分析

Functional implications of respiratory syncytial virus F sequence variability: a comparative analysis using contemporary RSV isolates.

作者信息

Stobbelaar Kim, Jacobs Lotte, Serrano-Cano Francisco I, Fransen Axelle, Van der Gucht Winke, Smet Annemieke, De Winter Benedicte Y, Cos Paul, de Vos Winnok, Van Hoorenbeeck Kim, Verhulst Stijn, Delputte Peter L

机构信息

Laboratory of Microbiology, Parasitology and Hygiene, Faculty of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

出版信息

mSphere. 2025 May 27;10(5):e0086024. doi: 10.1128/msphere.00860-24. Epub 2025 Apr 14.

DOI:10.1128/msphere.00860-24
PMID:40227055
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12108066/
Abstract

Respiratory syncytial virus (RSV) remains a major global health issue. Therapeutic options are limited, but new prophylactics, all targeting the fusion (F) glycoprotein, were recently licensed. Although F sequence variation is limited, it is unclear if and how this variability translates to phenotypical differences. We analyzed full F sequences of 105 contemporary RSV isolates, gathered from children presenting with acute lower respiratory tract infections. Based on F antigenic site variation, 20 isolates were selected for functional characterization. Although RSV F diversity is generally low, the overall mean pairwise distance between RSV-A strains is higher than RSV-B (0.014 vs 0.008, < 0.001). Sequence variability in the known monoclonal antibody (mAb)-binding sites seems insufficient to explain the divergent and often subgroup-dependent sensitivity to mAb neutralization. Despite comparable growth rates, mean syncytium size was higher (mean 61.68 [SD 24.51] vs 31.72 [SD 11.64], < 0.001), and mean syncytium frequency was lower (mean 25.37 [SD 9.20] vs 47.85 [11.52], < 0.001) in RSV-A strains. For all isolates, higher temperatures were associated with increased inactivation, although some RSV-A isolates displayed manifestly higher stability. Genomic and phenotypic variability among our contemporary RSV isolates was limited, with noticeable exceptions. The availability of new prophylactics targeting RSV F corroborates the importance of continued RSV surveillance to identify changes in the F sequence, including mutations that reduce mAb efficacy or lead to escape mutants. Surveillance should include both sequencing data and an evaluation of sensitivity to prophylactic antibodies, using contemporary clinical isolates.IMPORTANCERespiratory syncytial virus (RSV) is a major cause of respiratory infections in young children worldwide. Recent progress has led to new ways to prevent serious RSV-associated disease. The virus's fusion (F) protein is a key focus for vaccine development because it helps the virus enter host cells and is well conserved across different virus strains. However, it is unclear if small differences in the F protein sequence could affect how the virus behaves . In this study, we, therefore, analyzed 105 RSV samples from children under two who presented with respiratory infections. We selected 20 samples (12 RSV-A and 8 RSV-B) for functional testing, based on their F protein sequences. Phenotypic differences between clinical isolates and reference strains, such as virus stability at 4°C and susceptibility to monoclonal antibody neutralization, highlight the importance of using viruses isolated from recent clinical samples. Although significant functional differences were observed in traits related to the F protein, both between the RSV subgroups and within, the underlying molecular mechanisms remain unclear. Ongoing monitoring of RSV is critical to ensure current and future vaccines remain effective.

摘要

呼吸道合胞病毒(RSV)仍然是一个重大的全球健康问题。治疗选择有限,但最近有几种新的预防性药物获得许可,均靶向融合(F)糖蛋白。尽管F序列变异有限,但尚不清楚这种变异性是否以及如何转化为表型差异。我们分析了从患有急性下呼吸道感染的儿童中收集的105株当代RSV分离株的完整F序列。基于F抗原位点变异,选择了20株分离株进行功能表征。尽管RSV F的多样性总体较低,但RSV-A株之间的总体平均成对距离高于RSV-B株(0.014对0.008,<0.001)。已知单克隆抗体(mAb)结合位点的序列变异性似乎不足以解释对mAb中和的不同且通常依赖亚组的敏感性。尽管生长速率相当,但RSV-A株的平均合胞体大小更高(平均61.68[标准差24.51]对31.72[标准差11.64],<0.001),平均合胞体频率更低(平均25.37[标准差9.20]对47.85[11.52],<0.001)。对于所有分离株,较高温度与灭活增加相关,尽管一些RSV-A分离株表现出明显更高的稳定性。我们当代RSV分离株之间的基因组和表型变异性有限,但有明显例外。针对RSV F的新预防性药物的可用性证实了持续进行RSV监测以识别F序列变化(包括降低mAb效力或导致逃逸突变体的突变)的重要性。监测应包括测序数据以及使用当代临床分离株评估对预防性抗体的敏感性。

重要性

呼吸道合胞病毒(RSV)是全球幼儿呼吸道感染的主要原因。最近的进展带来了预防严重RSV相关疾病的新方法。该病毒的融合(F)蛋白是疫苗开发的关键重点,因为它有助于病毒进入宿主细胞,并且在不同病毒株中高度保守。然而,尚不清楚F蛋白序列中的微小差异是否会影响病毒的行为。因此,在本研究中,我们分析了105份来自两岁以下患有呼吸道感染儿童的RSV样本。我们根据其F蛋白序列选择了20份样本(12份RSV-A和8份RSV-B)进行功能测试。临床分离株与参考株之间的表型差异,如4°C下的病毒稳定性和对单克隆抗体中和的敏感性,凸显了使用从近期临床样本中分离的病毒的重要性。尽管在与F蛋白相关的性状上观察到了显著的功能差异,无论是在RSV亚组之间还是内部,但潜在的分子机制仍不清楚。持续监测RSV对于确保当前和未来疫苗仍然有效至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/43d23c08c9bd/msphere.00860-24.f009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/33d8ad9c18af/msphere.00860-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/3a54c3443b03/msphere.00860-24.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/05a854471c88/msphere.00860-24.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/0e9706027b05/msphere.00860-24.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/2800fadc5794/msphere.00860-24.f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/7767e7df56b5/msphere.00860-24.f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/70c3ee4334fe/msphere.00860-24.f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/dc577a5a1e74/msphere.00860-24.f008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/43d23c08c9bd/msphere.00860-24.f009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/33d8ad9c18af/msphere.00860-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/3a54c3443b03/msphere.00860-24.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/05a854471c88/msphere.00860-24.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/0e9706027b05/msphere.00860-24.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/2800fadc5794/msphere.00860-24.f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/7767e7df56b5/msphere.00860-24.f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/70c3ee4334fe/msphere.00860-24.f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/dc577a5a1e74/msphere.00860-24.f008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34df/12108066/43d23c08c9bd/msphere.00860-24.f009.jpg

相似文献

1
Functional implications of respiratory syncytial virus F sequence variability: a comparative analysis using contemporary RSV isolates.呼吸道合胞病毒F序列变异性的功能影响:使用当代呼吸道合胞病毒分离株的比较分析
mSphere. 2025 May 27;10(5):e0086024. doi: 10.1128/msphere.00860-24. Epub 2025 Apr 14.
2
Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.呼吸道合胞病毒(RSV)A和B当代及历史基因型中融合基因的序列变异性
PLoS One. 2017 Apr 17;12(4):e0175792. doi: 10.1371/journal.pone.0175792. eCollection 2017.
3
Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.分析 2009-2015 年韩国儿童在帕利珠单抗时代临床分离株中的呼吸道合胞病毒融合蛋白。
J Infect Chemother. 2019 Jul;25(7):514-519. doi: 10.1016/j.jiac.2019.02.013. Epub 2019 Mar 15.
4
Molecular epidemiology and phylodynamics of the human respiratory syncytial virus fusion protein in northern Taiwan.台湾北部人类呼吸道融合病毒融合蛋白的分子流行病学和系统发育动力学。
PLoS One. 2013 May 29;8(5):e64012. doi: 10.1371/journal.pone.0064012. Print 2013.
5
Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity.鉴定 N-糖基化位点在呼吸道合胞病毒融合蛋白在病毒复制、合胞体形成和抗原性中的作用。
Virus Res. 2019 Jun;266:58-68. doi: 10.1016/j.virusres.2019.04.006. Epub 2019 Apr 17.
6
A multi-center study on genetic variations in the fusion protein of respiratory syncytial virus from children with Acute Lower Respiratory Tract Infections in China during 2017-2021.一项关于 2017-2021 年期间中国急性下呼吸道感染儿童呼吸道合胞病毒融合蛋白基因变异的多中心研究。
Virol Sin. 2024 Oct;39(5):727-736. doi: 10.1016/j.virs.2024.09.002. Epub 2024 Sep 13.
7
Genomic characterization of circulating human respiratory syncytial viruses A and B in Kuwait using whole-genome sequencing.利用全基因组测序技术对科威特循环的人呼吸道合胞病毒 A 和 B 进行基因组特征分析。
Microbiol Spectr. 2024 Jul 2;12(7):e0015924. doi: 10.1128/spectrum.00159-24. Epub 2024 May 29.
8
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.呼吸道合胞病毒融合纳米颗粒疫苗免疫应答针对多个中和表位,有助于预防野生型和帕利珠单抗耐药突变病毒的挑战。
Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.
9
The molecular epidemiology of respiratory syncytial virus in Ontario, Canada from 2022-2024 using a custom whole genome sequencing assay and analytics package.2022年至2024年期间,在加拿大安大略省利用定制的全基因组测序检测方法和分析软件包开展呼吸道合胞病毒的分子流行病学研究。
J Clin Virol. 2025 Feb;176:105759. doi: 10.1016/j.jcv.2024.105759. Epub 2024 Dec 16.
10
Evaluation of the role of respiratory syncytial virus surface glycoproteins F and G on viral stability and replication: implications for future vaccine design.评价呼吸道合胞病毒表面糖蛋白 F 和 G 在病毒稳定性和复制中的作用:对未来疫苗设计的启示。
J Gen Virol. 2019 Jul;100(7):1112-1122. doi: 10.1099/jgv.0.001287. Epub 2019 Jun 11.

本文引用的文献

1
The molecular epidemiology of respiratory syncytial virus in Ontario, Canada from 2022-2024 using a custom whole genome sequencing assay and analytics package.2022年至2024年期间,在加拿大安大略省利用定制的全基因组测序检测方法和分析软件包开展呼吸道合胞病毒的分子流行病学研究。
J Clin Virol. 2025 Feb;176:105759. doi: 10.1016/j.jcv.2024.105759. Epub 2024 Dec 16.
2
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).从医学上脆弱的儿童中分离出的呼吸道合胞病毒株的分子和表型特征:尼司特韦单抗(MEDLEY)的 2/3 期随机、双盲、帕利珠单抗对照试验的探索性分析。
Vaccine. 2024 Oct 24;42(24):126276. doi: 10.1016/j.vaccine.2024.126276. Epub 2024 Sep 5.
3
Standardized Phylogenetic Classification of Human Respiratory Syncytial Virus below the Subgroup Level.人类呼吸道合胞病毒亚群以下的标准化系统发育分类。
Emerg Infect Dis. 2024 Aug;30(8):1631-1641. doi: 10.3201/eid3008.240209.
4
Direct-acting antivirals for RSV treatment, a review.直接作用抗病毒药物治疗 RSV,一篇综述。
Antiviral Res. 2024 Sep;229:105948. doi: 10.1016/j.antiviral.2024.105948. Epub 2024 Jul 5.
5
Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures.呼吸道合胞病毒A亚组和B亚组之间的差异及其对药物预防措施的影响。
Infect Dis Ther. 2024 Aug;13(8):1725-1742. doi: 10.1007/s40121-024-01012-2. Epub 2024 Jul 6.
6
Differential impact of COVID-19 non-pharmaceutical interventions on the epidemiological dynamics of respiratory syncytial virus subtypes A and B.COVID-19 非药物干预措施对呼吸道合胞病毒 A 型和 B 型流行动力学的差异影响。
Sci Rep. 2024 Jun 24;14(1):14527. doi: 10.1038/s41598-024-64624-1.
7
Efficacy and Safety of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Disease: An Updated Systemic Review and Meta-Analysis.帕利珠单抗预防呼吸道合胞病毒(RSV)疾病的疗效与安全性:一项更新的系统评价和荟萃分析
Cureus. 2023 Dec 31;15(12):e51375. doi: 10.7759/cureus.51375. eCollection 2023 Dec.
8
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.基于 mRNA 的 RSV 前体疫苗在老年人中的疗效和安全性。
N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079.
9
Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants.呼吸道合胞病毒融合前 F 亚单位疫苗:首个保护婴儿的母体疫苗的批准。
Paediatr Drugs. 2023 Nov;25(6):729-734. doi: 10.1007/s40272-023-00598-3.
10
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope.融合前稳定的呼吸道合胞病毒融合蛋白疫苗可诱导针对膜近端表位的抗体。
J Virol. 2023 Oct 31;97(10):e0092923. doi: 10.1128/jvi.00929-23. Epub 2023 Sep 22.